A study in Neuropharmacology reveals that a single dose of the psychedelic compound (R)-DOI significantly improves stress-coping behaviors and reduces inflammatory markers in mice subjected to social aggression.
A study in JAMA Network Open examined the acute adverse effects of therapeutic doses of psilocybin for treating depression and anxiety, focusing on its safety profile by assessing the occurrence of immediate side effects like headache, nausea, and elevated blood pressure among others.
Review uncovers that psychobiotics may offer supportive treatment for depression by restoring gut microbiome balance and positively influencing the microbiome-gut-brain axis, which is crucial for mental health and well-being.
Study reviews the advancements in pharmacological treatments for neuropsychiatric syndromes in neurodegenerative disorders, discussing the complexities of managing symptoms such as depression, disinhibition, apathy, psychosis, and agitation to improve patient care.